1. Home
  2. CAVA vs GKOS Comparison

CAVA vs GKOS Comparison

Compare CAVA & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CAVA Group Inc.

CAVA

CAVA Group Inc.

HOLD

Current Price

$82.02

Market Cap

8.1B

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$119.52

Market Cap

6.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAVA
GKOS
Founded
2006
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
6.9B
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
CAVA
GKOS
Price
$82.02
$119.52
Analyst Decision
Buy
Strong Buy
Analyst Count
20
14
Target Price
$84.89
$133.07
AVG Volume (30 Days)
3.5M
722.6K
Earning Date
05-27-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.54
N/A
Revenue
$1,179,664,000.00
$507,442,000.00
Revenue This Year
$22.75
$23.29
Revenue Next Year
$20.23
$27.74
P/E Ratio
$156.63
N/A
Revenue Growth
22.41
32.33
52 Week Low
$43.41
$73.16
52 Week High
$97.98
$130.23

Technical Indicators

Market Signals
Indicator
CAVA
GKOS
Relative Strength Index (RSI) 66.70 54.43
Support Level $62.15 $78.93
Resistance Level $91.96 $130.23
Average True Range (ATR) 4.16 4.99
MACD 1.79 0.71
Stochastic Oscillator 80.07 81.41

Price Performance

Historical Comparison
CAVA
GKOS

About CAVA CAVA Group Inc.

Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: